Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961776 · ClinicalTrials.gov registry record
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
A clinical trial of Rectal Adenocarcinoma, sponsored by Institut Paoli-Calmettes.
- Recruiting
- Registry status
- 39
- Enrollment target
- 2
- Study locations
NCT03961776: Recruiting study of Rectal Adenocarcinoma, sponsored by Institut Paoli-Calmettes.
NCT03961776 is a study of Rectal Adenocarcinoma that is actively recruiting participants, run by Institut Paoli-Calmettes. The registered enrollment target is 39 participants, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03961776, a study of Rectal Adenocarcinoma, is actively recruiting participants, sponsored by Institut Paoli-Calmettes.
- RECRUITING
- Registry status
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
Primary Outcome
Pathological complete response using AJCC criteria
Conditions Studied
Interventions
- DEVICE MRI-guided radiotherapy by on-board DWI sequences
Study Locations (2)
California
- University of California Los Angeles (UCLA) - Los Angeles
Bouches Du Rhone
- Institut Paoli Calmettes - Marseille
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2027-05 |
What NCT03961776 shows while recruiting
NCT03961776 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which MRI-guided radiotherapy by on-board DWI sequences is the first listed.
NCT03961776 reports a single indexed study location in California, Bouches Du Rhone.
Frequently Asked Questions
What is clinical trial NCT03961776 about?
NCT03961776 is a clinical study titled "Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems". feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
What is the current status of trial NCT03961776?
This trial is currently recruiting. The enrollment target is 39 participants. The study started on 2020-06-08. Estimated completion is 2027-05.
What conditions does trial NCT03961776 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma.
What interventions are being tested in trial NCT03961776?
The interventions under investigation include: MRI-guided radiotherapy by on-board DWI sequences (DEVICE).
Who is sponsoring clinical trial NCT03961776?
This trial is sponsored by Institut Paoli-Calmettes, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03961776 being conducted?
This trial has 2 study locations across California, Bouches Du Rhone. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03961776's enrollment target sits among peer trials
39 11th of 17 higher than 7 of 17 other Rectal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITING · Phase 3
-
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
RECRUITING · Phase 2
-
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
RECRUITING · Early Phase 1
-
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
- NCT04588545 · 39 participants · Phase 1
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy